[Therapeutic approaches using genetically modified cells].
Medicinal products containing genetically modified cells are, in most cases, classified as gene therapy and cell therapy medicinal products. Although no medicinal product containing genetically modified cells has been licensed in Europe yet, a variety of therapeutic strategies using genetically modified cells are in different stages of clinical development for the treatment of acquired and inherited diseases. In this chapter, several examples of promising approaches are presented, with an emphasis on gene therapy for inherited immunodeficiencies and on tumour immunotherapy with genetically modified T-cells expressing a chimeric antigen receptor or a recombinant T-cell receptor.
Paul-Ehrlich-Institut, Fachgebiet 6/2, Paul-Ehrlich-Straße 51-59, 63225, Langen, Deutschland.
Brigitte
B
Anliker
Paul-Ehrlich-Institut, Fachgebiet 6/2, Paul-Ehrlich-Straße 51-59, 63225, Langen, Deutschland.
Matthias
M
Renner
Paul-Ehrlich-Institut, Fachgebiet 6/2, Paul-Ehrlich-Straße 51-59, 63225, Langen, Deutschland. matthias.schweizer@pei.de.
Matthias
M
Schweizer
D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D005818:Genetic Engineering / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000235:genetics / Q000628:therapy; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000235:genetics / Q000628:therapy; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D011993:Recombinant Fusion Proteins; D013601:T-Lymphocytes / Q000276:immunology; D035703:Therapies, Investigational / Q000379:methods*
D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins
Cell therapy; Chimeric antigen receptor/T-cell receptor; Gene therapy; Genetically modified cells; Inherited immunodeficiency